SolGel Technologies (SLGL)
(Delayed Data from NSDQ)
$0.89 USD
+0.03 (3.32%)
Updated Apr 26, 2024 01:33 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SLGL 0.89 +0.03(3.32%)
Will SLGL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLGL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLGL
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
SLGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Other News for SLGL
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Announces Generic Drug Application for Psoriasis Treatment
Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve
Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M
Sol-Gel Technologies: Q4 Earnings Insights